Paul B. Chapman, MD

home / authors / paul-b-chapman-md

Articles

Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

Paul B. Chapman, MD

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Dr. Paul B. Chapman on Optimizing Targeted Therapy in Melanoma

Dr. Paul B. Chapman on Optimizing Targeted Therapy in Melanoma

Paul B. Chapman, MD

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Published: January 24th 2025 | Updated: February 6th 2025

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

Published: September 13th 2024 | Updated: November 25th 2024

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.

Published: April 21st 2025 | Updated: April 26th 2025

Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.